# Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins

> **NCT07016841** · — · RECRUITING · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 120 (estimated)

## Conditions studied

- End Stage Renal Disease on Dialysis

## Interventions

- **DEVICE:** pHA130 hemoperfusion device
- **DEVICE:** HD/HDF
- **DEVICE:** HA130 hemoperfusion device

## Key facts

- **NCT ID:** NCT07016841
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016841, "Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07016841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*